Pfizer (PFE) Cash from Discontinued Operations (2010 - 2022)

Pfizer (PFE) has reported Cash from Discontinued Operations for 7 consecutive years, with 5000000.0 the latest figure, recorded in Q3 2022.

• In Q3 2022, Cash from Discontinued Operations fell 129.41% year-over-year to 5000000.0; the TTM figure through Jul 2022 stood at 315000000.0 (down 109.53% YoY), while the FY2021 annual figure was 343000000.0, down 108.88% from the prior year.
• Cash from Discontinued Operations improved to 5000000.0 in Q3 2022 per PFE's latest filing, from 327000000.0 in the prior quarter.
• Across five years, Cash from Discontinued Operations topped out at 2414000000.0 in Q3 2020 and bottomed at 327000000.0 in Q4 2021.
• Historically, Cash from Discontinued Operations has averaged 564428571.43 across 3 years, with a median of 17000000.0 in 2021.
• Annual changes were most pronounced in 2021 — Cash from Discontinued Operations tumbled 98.07% — and 2022, when it slumped 129.41%.
• Pfizer's Cash from Discontinued Operations stood at 2414000000.0 in 2020, then tumbled by 113.55% to 327000000.0 in 2021, then surged by 98.47% to 5000000.0 in 2022.
• Business Quant data shows PFE's Cash from Discontinued Operations at 5000000.0 in Q3 2022, 327000000.0 in Q4 2021, and 17000000.0 in Q3 2021.